ClinicalTrials.gg

Program

inaticabtagene autoleucel

Also written as “single dose of CNCT19”, “Inaticabtagene Autoleucel Injection” and “Inaticabtagene autoleucel Injection”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune · Burkitt Lymphoma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by Juventas Cell Therapy.

Furthest: phase 2, since Oct 8, 20208 company-led studies, 6 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Juventas Cell Therapy86 open or runningphase 2since Oct 8, 2020Jan 11, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2020First studies: 2 phase 1 studiesFirst studyNCT04232826, NCT04230473
  2. Oct 8, 2020Phase 2 study in Lymphoma, Non-HodgkinNCT04586478 · 60 planned · China
  3. Dec 9, 2020Phase 2 study in RecurrenceNCT04684147 · 100 planned · China
  4. Dec 5, 2022Phase 2 study in Burkitt LymphomaNCT05667506 · 47 planned · China
  5. Mar 4, 2024Early phase 1 study in Lupus Erythematosus, SystemicNCT06316791 · 24 planned · China
  6. Feb 6, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06826430 · 12 planned · China
  7. Jul 21, 2025Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07091370 · 12 planned

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07091370Anemia, Hemolytic, Autoimmune1Not yet recruitingSep 30, 202612
NCT06826430Purpura, Thrombocytopenic, Idiopathic · China1RecruitingMar 31, 202612
NCT06316791Lupus Erythematosus, Systemic · ChinaEarly 1RecruitingDec 13, 202524
NCT05667506Burkitt Lymphoma · China2RecruitingMay 30, 202547
NCT04684147Recurrence · China2RecruitingSep 22, 2022100
NCT04586478Lymphoma, Non-Hodgkin · China2RecruitingMar 30, 202460
NCT04232826Diffuse Non-Hodgkin Lymphoma · China1CompletedJan 1, 20219
NCT04230473Recurrence · China1CompletedDec 1, 202010

How it is read

Names in the registry

  • “single dose of CNCT19”, 6 entries
  • “Inaticabtagene Autoleucel Injection”, 1 entry
  • “Inaticabtagene autoleucel Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.